1 TITLE PAGE

2

3 **Title:**

- 4 Performance of a Computational Phenotyping Algorithm for Sarcoidosis Using
- 5 Diagnostic Codes in Electronic Medical Records: A Pilot Study from Two Veterans
- 6 Affairs Medical Centers
- 7
- 8 Authors:
- 9 Mohamed I Seedahmed, MD, MPH^{1,2*}, Izabella Mogilnicka, MD^{1,5*}, Siyang Zeng, MS^{1,4},
- 10 Gang Luo, PhD⁴, Charles McCulloch, PhD³, Laura Koth, MD^{2γ}, Mehrdad Arjomandi,
- 11 **MD**^{1,2 γ}
- 12 ¹ San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
- 13 ² Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of
- 14 Medicine, University of California San Francisco, California, USA
- ³ Department of Epidemiology & Biostatistics, University of California San Francisco,
- 16 California, USA
- ⁴ Department of Biomedical Informatics and Medical Education, School of Medicine,
- 18 University of Washington, Seattle, Washington, USA
- ⁵ Department of Experimental Physiology and Pathophysiology, Laboratory of the Centre for
- 20 Preclinical Research, Medical University of Warsaw, Warsaw, Poland
- 21
- ^{*}MIS and IM: These authors contributed equally to this work.
- $^{\gamma}$ MA and LK: These authors share senior authorship.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

24 Email Addresses | ORCID iDs:

- 25 MIS: mohamed.seedahmed@ucsf.edu | https://orcid.org/0000-0002-7446-7346
- 26 IM: izabella.mogilnicka@gmail.com | https://orcid.org/0000-0002-5735-8375
- 27 SZ: siyang.zeng@ucsf.edu | https://orcid.org/0000-0001-9346-301X
- 28 GL: luogang@uw.edu | https://orcid.org/0000-0001-7217-4008
- 29 CM: charles.mcculloch@ucsf.edu | https://orcid.org/0000-0002-1279-6179
- 30 LK: laura.koth@ucsf.edu | https://orcid.org/0000-0001-9541-3622
- 31 MA: mehrdad.arjomandi@ucsf.edu | https://orcid.org/0000-0002-0116-9217
- 32
- 33 Word Count: 3,829 words.
- 34
- 35 Corresponding Author:
- 36 Mohamed I Seedahmed, MD, MPH
- 37 Division of Pulmonary, Critical care, allergy and Immunology, and Sleep.
- 38 Department of Medicine, University of California, San Francisco
- 39 University of California San Francisco Helen Diller Medical Center
- 40 513 Parnassus Ave.
- 41 HSE 1314, Box 0111
- 42 San Francisco, CA 94143
- 43 Office: (415) 476-0735
- 44 Fax: (415) 502-2605
- 45 EMAIL: mohamed.seedahmed@ucsf.edu

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

46 **Authors' Contributions:**

- 47 All authors read and approved the final manuscript.
- 48 Conceived and designed the study research: MIS, LK, MA
- 49 Developed study protocol: MIS, LK, MA
- 50 Worked on the methods: MIS, IM, SZ, CM, LK, MA
- Analyzed and Interpreted data: MIS, IM, SZ, CM, LK, MA 51
- 52 Prepared and/or edit the manuscript: MIS, IM, GL, CM, LK, MA

53

54 **Keywords:**

Sarcoidosis, Electronic Medical Records (EMR), Computational Phenotyping, Diagnostic 55

Codes, Veterans Affairs (VA), ATS Practice Guidelines. 56

57

58 **Highlights**

- 59 • Identifying sarcoidosis cases using diagnostic codes in EMR has low accuracy.
- 60 • "Unstructured data" contain information useful in identifying cases of sarcoidosis.
- 61 • Computational algorithms could improve the accuracy and efficiency of
- 62 case identification in EMR.
- 63 • We introduce a new scoring system for assessing healthcare providers' compliance with
- 64 the American Thoracic Society (ATS) practice guideline.
- 65 • Compliance scoring could help automatically assess sarcoidosis patients' care delivery.

It is made available under a CC-BY-NC-ND 4.0 International license

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

66 ABSTRACT (250 words)

- 67 Background-The accuracy of identifying sarcoidosis cases in electronic medical records
 68 (EMR) using diagnostic codes is unknown.
- 69 Methods-To estimate the statistical performance of using ICD-9 and ICD-10 diagnostic
- 70 codes in identifying sarcoidosis cases in EMR, we searched the San Francisco and Palo Alto
- 71 Veterans Affairs (VA) medical centers EMR and randomly selected 200 patients coded as
- 72 sarcoidosis. To further improve diagnostic accuracy, we developed an "index of suspicion"
- algorithm to identify probable sarcoidosis cases based on clinical and radiographic features.
- 74 We then determined the positive predictive value (PPV) of diagnosing sarcoidosis by two
- computational methods using ICD only and ICD plus the "index of suspicion" against the
- 76 gold standard developed through manual chart review based on the American Thoracic
- 77 Society (ATS) practice guideline. Finally, we determined healthcare providers' adherence to
- 78 the guidelines using a new scoring system.
- **Results-**The PPV of identifying sarcoidosis cases in VA EMR using ICD codes only was 71%
 (95%CI=64.7%-77.3%). The inclusion of our construct of "index of suspicion" along with the
 ICD codes significantly increased the PPV to 90% (95%CI=85.2%-94.6%). The care of
 sarcoidosis patients was more likely to be classified as "Fully" or "Substantially" adherent with
- the ATS practice guideline if their managing provider was a specialist (45% of primary care
- 84 providers vs. 74% of specialists; P=0.008).
- 85 **Conclusions-**Although ICD codes can be used as reasonable classifiers to identify
- 86 sarcoidosis cases within EMR, using computational algorithms to extract clinical and
- 87 radiographic information ("index of suspicion") from unstructured data could significantly
- 88 improve case identification accuracy.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

89 INTRODUCTION

90	Sarcoidosis is a complex disease of unknown etiology that can involve multiple organs,
91	with no universal and standardized measures that fully secure the final diagnosis.[1–3] In fact,
92	only recently the American Thoracic Society (ATS) published its first practice guideline to
93	provide recommendations for diagnosing sarcoidosis and the necessary screening tests.[3] The
94	ATS practice guideline for diagnosis requires the presence of specific clinical and radiographic
95	features, tissue biopsy revealing non-necrotizing granulomas, and exclusion of alternative
96	conditions that can mimic sarcoidosis.[1,3,4]

97 Electronic medical record (EMR) data are commonly used in research and by healthcare 98 systems, including the Department of Veterans Affairs, to predict outcomes or assess care 99 quality.[5] EMR data are generally captured in two forms: 1) structured data such as billing 100 codes like International Classification of Disease (ICD) codes, laboratory test results, 101 procedural codes, and 2) *narrative or unstructured data* such as progress notes, pathology 102 reports, and imaging reports. Unstructured data contain many more details of the clinical 103 conditions, but extracting these details is challenging and time-consuming. In contrast, 104 structured data are easier to search and offer the promise to identify cases computationally 105 using diagnostic codes. But, diagnostic codes can be inaccurate and not easily verifiable, 106 particularly for the case definition of complex diseases such as sarcoidosis.[6–8] Thus, there is 107 a need to develop automated algorithms to verify the final diagnosis of sarcoidosis using 108 unstructured data by incorporating the ATS diagnostic criteria.

109 The goals of this study are twofold. First, we sought to estimate the statistical 110 performance of using diagnostic codes (ICD-9 and 10) to identify patients with sarcoidosis in 111 the United States Veterans Affairs (VA) EMR through the VA Informatics and Computational 112 Infrastructure (VINCI) via applying a recently published ATS practice guideline. Second, we

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 113 investigate healthcare providers' practice patterns and determine how adherent these patterns
- are with the new practice guideline issued by the ATS. This study will help researchers and
- 115 healthcare systems understand the healthcare providers' compliance with these new
- 116 recommendations and conduct research using administrative databases.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

117 METHODS

118 Study Design

We determined the statistical performance of using diagnostic codes (the International 119 120 Classification of Diseases, Ninth and Tenth Revisions codes; ICD-9 and ICD-10) to identify 121 patients with sarcoidosis from the EMR. First, by identifying patients with ICD diagnosis code 122 of sarcoidosis, and then performing a comprehensive chart review of the entire unstructured 123 data to ascertain the true diagnosis of sarcoidosis. Furthermore, to improve the diagnostic 124 accuracy using ICD code alone, we generated an "index of suspicion" criteria from 125 unstructured clinical and radiographic data, but not histopathologic data, as a second decision point along with ICD code. We then determined the positive predictive value of both the use 126 of ICD code and ICD code plus "index of suspicion" to determine whether the use of "index 127 128 of suspicion" could improve the accuracy of identifying sarcoidosis cases in EMR regardless 129 of tissue biopsy availability. Finally, we investigated the relevant healthcare utilization among 130 the identified patients to determine healthcare providers' adherence to the ATS practice 131 guideline.

132

133 Data Source

This is a retrospective cohort study of electronic medical records (EMR) available from 134 135 the Veterans Affairs Informatics and Computational Infrastructure (VINCI). Developed by the 136 VA Health Services Research & Development (HSR&D) to improve veterans' healthcare, VINCI provides access to comprehensive and integrated veterans' national datasets that are de-137 138 identified and the necessary computational and analytical tools in a secure, high-performance 139 computing environment [9]. The University of California San Francisco Institutional Review 140 Board and the Veterans Health Administration Research and Development Committee 141 approved this study.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

142 **Data Collection**

143 We searched the EMR data in VINCI from 1989 to 2019 and identified all patients coded as sarcoidosis cases in the VA healthcare system, as defined by documentation of the 144 145 ICD-9 and 10 codes of 135 and D.86 (including all subcodes), respectively. Data were 146 extracted through executing Structured Query Language (SQL) queries in a SQL Server 2017 147 database.

148

149 We then performed a comprehensive and thorough manual chart review of the 150 unstructured data (available clinical notes, pathology reports, radiology reports, and laboratory 151 test results) to determine the accuracy of the ICD-9 or 10 code-based diagnosis of sarcoidosis among cases. To limit the required chart review to a manageable level, we reviewed a total of 152 153 200 cases out of the 14,833 identified. Because our access to the detailed medical records was 154 limited to two VA medical centers (San Francisco VA [SFVA] and Palo Alto Medical Centers 155 [PAVA]), the 200 patients coded as sarcoidosis were selected from those two centers. We 156 stratified the list of sarcoidosis cases from the two centers by site and used the "lottery" method 157 to select 100 patients from each site randomly.[10]

158 Two independent reviewers (MIS, IM) confirmed the diagnoses of sarcoidosis by 159 performing a manual chart review of the 200 cases in the VA EMR, Computerized Patient 160 Record System (CPRS), and based on the ATS diagnostic criteria (clinical, radiographic, 161 pathological findings, and exclusion of other causes).[3] This approach was considered the 162 "gold standard" methodology for diagnostic accuracy.

163 Given that in clinical practice, not all suspected patients will have a tissue biopsy, we generated an "index of suspicion" for sarcoidosis to identify patients with probable sarcoidosis 164 based on clinical and radiographic information and regardless of the availability of biopsy data. 165

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

166 The "index of suspicion" was defined based on the interpretation of available unstructured data 167 from both clinical and radiographic findings without the inclusion of tissue biopsy results if available and was used to determine the likelihood of an individual having sarcoidosis. Upon 168 169 completing the chart review, each patient was assigned to one of two groups of "high index of 170 suspicion" if the clinical and radiological presentations were supportive of sarcoidosis, or "low 171 index of suspicion" if clinical and radiological findings were not consistent with sarcoidosis. 172 We then classified the patients into three groups: (1) Patients with a high index of suspicion 173 and documented histopathological evidence of non-necrotizing granulomas were categorized 174 as "probable sarcoidosis with confirmed biopsy"; (2) Those with a high index of suspicion and 175 either no documented biopsy in the EMR or a biopsy showing no histopathological evidence of non-necrotizing granulomas were categorized as "probable sarcoidosis without confirmed 176 177 biopsy"; and (3) those with a low index of suspicion were classified as "unlikely sarcoidosis."

This approach was used to compare the statistical performance of the two methods (ICD code alone versus ICD code with "index of suspicion") in identifying sarcoidosis patients from the EMR. As we started with a random sample of those with sarcoidosis diagnostic codes (ICD codes 135 or D86), the further restriction of the sample to those with "high index of suspicion" is still a random sample of the combination of both ICD codes and "index of suspicion."

183 **Disease-related Variables**

Organ involvement was assessed based on the clinical history obtained from physicians' notes and imaging and biopsy reports available in CPRS. For this assessment, to adjust for the variability in providers' documentation, we adapted a set of criteria previously introduced in the NIH-sponsored Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study.[11]

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

189 We collected the following data from chart review: clinical site (SFVA or PAVA), 190 gender, race, ICD-9 and 10 code for sarcoidosis (135 and D86), index date of ICD code (entry date of the ICD code), specialty visits (specialty notes available), the pathological diagnosis 191 192 from any available biopsy, organ involvement (as described in Figure 2), Scadding staging of 193 chest x-ray (as described in radiology reports), history of bilateral hilar lymphadenopathy 194 (based on radiology reports and clinical notes), pulmonary function test (PFT) pattern (as 195 reported in PFT reports), vitamin D levels (25 [OH]D and 1,25[OH]D), and finally the 196 treatment status of sarcoidosis. Besides, we checked whether other imaging and laboratory 197 reports were performed and available in EMR as part of diagnostic workup and sarcoidosis 198 management; including echocardiography, 12-lead electrocardiogram (ECG), chest x-ray, 199 chest computed tomography (CT), cardiac magnetic resonance imaging (MRI) or positron 200 emission tomography (PET)/ CT, or abdominal CT scan or ultrasound.

Pathological diagnoses were categorized into "primary" histopathological if it was available in the pathology report domains, or "secondary" if the data was only available in clinical note domains due to either a remote history of biopsy or the biopsy being performed outside of the VA. The PFT reports at SFVA and PAVA used Crapo reference equations to calculate the Lower Limit of Normal (LLN) values for spirometry and lung volume measurements.

Using the clinical data from chart abstraction, we classified the patients into the clinical phenotypes proposed by the GRADS study with some modifications.[11] Because of the variability of available data needed to confirm multiple organ involvement from EMR chart review, we considered three or more organ involvement (instead of five or more as defined in the GRADS study) to categorize "multiorgan phenotype."

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

212 Finally, we created a scoring system to estimate the physicians' compliance with the 213 recently published ATS clinical practice guideline.[3] For this analysis, four variables were 214 used in the scoring system: (1) having an ophthalmology visit, (2) 12-lead EKG, (3) chest X-215 ray, and (4) vitamin D measurements (25-(OH) D and 1,25(OH) D) within one year after the 216 index date of ICD code. Each variable was given a score of three, and each patient could have 217 a total score of 12. We classified the physicians' compliance into four categories based on the score: "Fully," "Substantially," "Partially," or "Non-compliant" for scores of 12, 9-11, 5-8, or 218 219 <5 points, respectively. This scoring system was applied to all probable sarcoidosis patients 220 with or without histopathology confirmation. Furthermore, the role of primary versus specialty 221 care evaluation and management was examined by comparing the healthcare providers' 222 compliance score.

223 Statistical Analyses

224 All statistical analyses were performed with R software (RStudio, version 1.2.5, Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics were computed 225 226 to summarize the data. Categorical variables were presented as the frequency in percentages 227 and continuous data as means and standard deviations. We estimated the positive predictive 228 value (PPV) of the two computational diagnostic criteria for sarcoidosis described above (ICD 229 codes only and ICD codes along with "index of suspicion"). The PPV of the criterion of using 230 ICD code only was calculated as the number of patients verified to have sarcoidosis by chart 231 review ("gold standard" or true positives) divided by the total number of patients with an ICD-232 9 or 10 diagnostic code of sarcoidosis. The PPV of the criterion of using ICD codes and "index 233 of suspicion" use was calculated as the number of patients verified to have sarcoidosis ("gold 234 standard" or true positives) divided by the total number of patients with a high index of 235 suspicion. We computed the 95% confidence intervals (CI) using the exact binomial method. 236 For our estimates, the significance was defined as P < 0.05.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 237 To determine whether it is worth interpreting the developed contingency table that
- 238 compares the healthcare providers' compliance score by primary versus specialty care, we
- computed the chi-squared test of significance.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

240 **RESULTS**

241 Patients' Characteristics

A total of 14,833 patients with at least one ICD-9 or 10 diagnostic code of sarcoidosis 242 243 were identified (Figure 1). The study cohort included 200 patients identified by ICD codes of 244 sarcoidosis: 169 with ICD-9 code of 135 and 39 with ICD-10 code of D.86 (Table 1). Of the 245 200 patients, 158 had a "high index of suspicion" for sarcoidosis based on clinical and 246 radiographic findings. Of those, 142 had confirmed sarcoidosis based on histopathological 247 evidence of non-necrotizing granuloma and were classified as "probable sarcoidosis with 248 confirmed biopsy." The remaining 16 patients with a "high index of suspicion" did not undergo 249 a biopsy and were classified as "probable sarcoidosis without confirmed biopsy" (Figure 2). No patient had nondiagnostic biopsy results for sarcoidosis. 250

251 Among those patients with probable sarcoidosis (with and without confirmed biopsy), 252 90% (142/158) were males (Table 1), and there was a higher representation of African 253 Americans than non-Hispanic Whites (54% (85/158) vs. 33% (52/158), respectively). Overall, 254 90% (143/158) had a predominant pulmonary phenotype, and 29% (45/158) had a multi-organ 255 disease that included pulmonary. Among those with pulmonary phenotype, 28% (36/129), 22% 256 (28/129), and 19% (25/129) had restrictive, obstructive, and mixed lung function patterns, 257 respectively. The majority were in Scadding stage II (32%, 47/145), followed by Stage 0 and 258 Stage 1 (20% (29/145) and 18% (26/145), respectively). There was no significant difference in 259 age between those who did and those who did not have a biopsy performed to diagnose 260 sarcoidosis (mean age= 65.5 vs. 69.3, P= 0.18, respectively). In terms of clinical phenotypes, 261 the most common phenotype was multiorgan (33%, 52/158), followed by stage II or III treated 262 (29%, 45/158). Our study cohort did not include any individuals with acute presentation (acute, 263 untreated). Some patients with remitting phenotype overlapped with Groups 2 and 4 (Table 1) 264 (Figure 3).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

265 Diagnostic Accuracy of ICD Codes

266	We then calculated the positive predictive value (PPV) of using ICD codes to identify
267	VA patients that met the ATS definition of sarcoidosis from the VINCI database. For this
268	calculation, we used the curated dataset of 200 patients. The estimated PPV of using only ICD
269	codes was 71% (95% CI= 64.7%-77.3%). The inclusion of our construct of "index of suspicion"
270	along with the ICD codes into the identification of sarcoidosis increased the PPV estimate
271	significantly to 90% (95%CI= 85.2%-94.6%) (Table 2), as the initial sarcoidosis cohort was
272	restricted to the patients with "high index of suspicion."

273

274 Providers' Compliance with the ATS Clinical Practice Guideline

Among those with probable sarcoidosis (with and without biopsy), 13% were managed by primary care providers only, 51% (81/158) were managed by pulmonary physicians only, and pulmonary physicians managed 36% (57/158) along with other specialties such as ophthalmology or cardiology. The specialty care visits occurred in the context of diagnosis or management of the disease.

280

Within one year of the entry date of the ICD code of sarcoidosis, 91% (143/158) of patients had at least one chest x-ray, 83% (131/158) had at least one EKG, and 84% (133/158) had at least one visit to an ophthalmologist. In addition, 53% (82/158) had 25(OH)D, and 23% (36/158) had 1, 25(OH)D, including 20% (32/158) who had both measurements (**Table 1**).

285

Among the patients with probable sarcoidosis (with and without biopsy), 70% (111/158) had managing providers who were "Fully" or "Substantially" compliant with the ATS practice guideline based on our scoring system (**Table 3**). The majority of those patients, 92% (102/111), were managed by specialists, including pulmonary physicians, while primary

- 290 care providers managed 8% (9/111). Among the 30% (47/158) patients whose care only met
- 291 the "Partially compliant" or "Non-compliant" definition based on our scoring system, 23%
- (11/47) were managed by primary care providers (Figure 4). This result indicates that the care 292
- 293 of sarcoidosis patients was more likely to be classified as "Fully" or "Substantially" adherent
- with the ATS practice guideline if their managing provider was a specialist (45% [9/20] of 294
- 295 primary care providers vs. 74% [102/138] of specialists, P= .008) (Table 4).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

296 **DISCUSSION**

297 In this retrospective cohort study of Department of Veterans Affairs EMR, we evaluated 200 randomly selected patients diagnosed with sarcoidosis from the San Francisco 298 299 and Palo Alto Veterans Affairs Medical Centers. We found that using ICD-9 and 10 codes to 300 identify sarcoidosis patients within EMR has a relatively low accuracy (PPV of 71% 301 [95%CI= 64.7%-77.3%]) of detecting patients with "probable sarcoidosis" as defined by the 302 ATS clinical practice guideline. We also demonstrated that including an "index of suspicion" 303 that incorporates only the clinical and radiographical data allows for a significant increase in 304 diagnostic accuracy (PPV of 90% [85.2%-94.6%]), as the initial sarcoidosis cohort was restricted to the patients with "high index of suspicion." This "index of suspicion," which 305 306 was developed based on the ATS clinical practice guideline [3], could be executed by manual 307 chart review of the available clinical and radiographic data and could potentially be adapted 308 for automated chart review algorithms using natural language processing and machine 309 learning in EMR. Furthermore, we found that the care provided by specialists was more likely to be "Fully" or "Substantially" compliant with the ATS practice guideline compared 310 311 to primary care providers.

312

This randomly selected cohort of 200 Veterans with sarcoidosis diagnosis consisted of 313 314 90% men and 10% women. While the sex distribution in our study was different from the 315 ACCESS study[12], it is closely reflective of the veterans' population demographics.[13] 316 This study further confirmed the higher prevalence of sarcoidosis in African-Americans 317 (54%) compared to Caucasians (33%), which has been previously reported by many other 318 sarcoidosis epidemiology studies [14–18]. At the same time, the study population was racially diverse, highlighting the potential utility of the VA EMR for studying sarcoidosis in 319 320 populations of people of color.[19]

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

321 The novelty of this study is the development of a scoring system to objectively measure 322 physicians' compliance with the latest ATS practice guideline. Adherence to recommendations 323 might allow for earlier interventions in sarcoidosis management and ultimately improve 324 outcomes by delaying or preventing the development of morbid phenotypes. Variables used in 325 this scoring system included ophthalmology visit, 12-lead EKG, chest x-ray, and vitamin D 326 levels measurements within one year of the entry date of the ICD code. These variables were 327 chosen based on their utility and importance.[3] Not all tests and measurements discussed in 328 the guidelines have been included in our scoring system. Yet, we believe it can be easily 329 modified to include other clinical variables. Notably, a longitudinal analysis of the association 330 between physicians' compliance with the recommendations and clinical outcomes in 331 sarcoidosis could provide direction for future investigations and ultimately help better guide 332 clinical practice to be used as a metric to assess the improvement of the care delivery for 333 sarcoidosis patients.

334

335 Using ICD codes alone to extract health information is far more convenient than the 336 time-consuming manual review process of narrative datasets in unstructured data.[8] However, 337 using ICD codes to identify sarcoidosis cases in large datasets with thousands of patients poses several practical challenges. First, given the heterogeneity of sarcoidosis, it is challenging to 338 339 confirm the disease's presence efficiently. The verification process requires careful analysis of 340 the available narrative data such as progress notes, imaging reports, and pathology reports to 341 establish the case definition based on the sarcoidosis diagnostic criteria.[3] Second, the precise 342 identification of the type of organ involvement through EMR is a complex process and requires 343 a thorough review of unstructured data. Although there are sub-codes for ICD diagnostic codes 344 that aim to capture various organ involvement, healthcare providers may or may not be familiar 345 with those sub-codes and may or may not use them correctly. Moreover, there are no specific

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

346 ICD codes for classifying some of the various organ involvement in sarcoidosis (such as central 347 nervous system or GI tract).[20] Third, ICD codes do not determine the extent of disease, such as that described by chest x-ray stages [21], due to a lack of ICD codes for different stages of 348 349 pulmonary sarcoidosis.[20] Analysis of pulmonary features requires a manual review of every 350 patient's radiology reports and cannot be performed using only ICD codes alone. Finally, ICD 351 codes do not specify the various sarcoidosis presentations such as acute, remitting, or chronic 352 disease.[11,20] Thus, they cannot be used to classify patients into previously described 353 phenotype groups.

354

355 The definition of clinical phenotypes has become an essential goal for the sarcoidosis scientific community, as genetic studies have identified different patterns of gene expression 356 357 associated with disease severity and disease course.[22,23] In 2015, the National Heart, Lung, 358 and Blood Institute (NHLBI) held a workshop to leverage current scientific knowledge and 359 defining platforms to address disease disparities, identify high-risk phenotypes, and improve 360 sarcoidosis outcomes [24]. Nine different steps and research strategies were recommended to 361 expand the scope of sarcoidosis research, including EMR-based research to provide a unified, 362 multidisciplinary approach to bring together stakeholders interested in reducing the burden and severity of sarcoidosis. However, the major barrier in the efficient use of EMR data is the 363 364 accurate extraction of research-quality variables, case definitions, and outcomes.[25] Thus, the 365 rapid identification of cases and extraction of relevant clinical variables from EMR using 366 computable phenotype algorithms have emerged as an important next step in EMR-based 367 research. Computable phenotype definitions are also essential to conducting pragmatic clinical 368 trials and comparative effectiveness research, increasing the healthcare system's capacity to 369 deliver Precision Medicine effectively.[26]

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

371 The two most commonly applied approaches to defining computable phenotypes are: 372 (1) a "*high-throughput*" phenotype algorithm using only structured data (traditionally, the ICD 373 diagnosis codes). (2) a "low-throughput" phenotype algorithm that accesses structured and 374 unstructured data to develop a sequential flow chart that should end with a case definition. 375 Such a low-throughput approach employs high-performance computational tools (such as natural language processing [**NLP**]) to process text and extract information utilizing linguistic 376 377 rules instead of labor-intensive manual review by researchers.[6] This approach should 378 streamline the development of registries and help enrich EMR-based research studies.[27] Our 379 study highlights the need for the development of such automated methods to improve the 380 computational case-definition of sarcoidosis and other high-quality sarcoidosis-related 381 research variables, such as determining the date of the diagnosis, organ involvements, Scadding 382 stages, and the clinical status (acute, chronic, acute on the chronic or remitting disease).

383

384 Our study has several limitations. First, we used the ICD diagnosis code's entered date 385 as the surrogate time point to establish the patients' care with active sarcoidosis or re-386 establish the care for those with remitting disease. This approach is different from what 387 sarcoidosis researchers traditionally use as a surrogate to determine the date of diagnosis, 388 which is the date of performing the biopsy. However, because the ICD diagnosis code's date 389 is more relevant for assessing the managing healthcare providers' compliance, we chose to 390 take the above approach. Second, in the cases where the biopsy report was unavailable (either 391 due to a remote history of biopsy or biopsy performed outside the VA), we relied on the 392 "secondary" histopathological reports documented in the providers' narrative within the 393 clinical notes. This approach made the diagnosis of sarcoidosis less robust because 394 confirmatory biopsy reports in those patients were not directly verifiable. However, we used 395 the index of suspicion approach to define probable sarcoidosis cases regardless of whether

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

396	there was a confirmatory biopsy report available, which is consistent with the diagnostic
397	algorithm recommended by the ATS practice guideline.[3] Last, the generalizability of our
398	findings in VA EMR to other populations could be limited because the Veterans form a
399	special population with different demographics and exposures from the general population.
400	However, the US Veterans Affairs Healthcare System EMR data cover over 22 million
401	Veterans across the US and over 14,000 patients with sarcoidosis ICD diagnosis codes,
402	providing an enormous number of patients to study a rare disease.

403

404 Conclusion

405 Although ICD codes can be used as reasonable classifiers to identify sarcoidosis cases 406 within EMR, using computational algorithms to extract clinical and radiographic information 407 ("index of suspicion") from unstructured data could significantly improve case identification 408 accuracy. Using automated emerging methods (such as NLP) to develop a novel sarcoidosis-409 specific computational phenotype algorithm could increase the efficiency of identifying these 410 cases from large healthcare databases. Furthermore, we found that specialists are more likely 411 than primary care providers to be "Fully" or "Substantially" compliant with the ATS clinical 412 practice guideline. This finding calls attention to the importance of examining the association 413 between physicians' compliance with the recommendations and clinical outcomes 414 longitudinally.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

415 **TABLES:**

- Table 1. Distribution of characteristics and clinical phenotype groups of patients with 416
- 417 probable sarcoidosis ^a (with and without confirmed biopsy)

	Probable Sarcoidosis ^a		
	Probable sarcoidosis with confirmed biopsy	Probable sarcoidosis without confirmed biopsy	
	N (%)	N (%)	p-value
Characteristics	142 (90)	16 (10)	
Age (mean years ±SD)	65.5 ±10.8	69.3 ±10.3	0.18
Gender			
М	127 (89.4)	15 (93.8)	0.50 (
F	15 (10.6)	1 (6.2)	0.59 °
Race			
African American	74 (52.1)	11 (68.8)	
Non-Hispanic White	49 (34.5)	3 (18.8)	
Hispanic White	3 (2.1)	0 (0)	0.62 ^b
Unknown	12 (8.5)	2 (12.5)	
Other	4 (2.8)	0 (0)	
ICD codes for sarcoidosis			
ICD-9	98 (69)	10 (62.5)	0.50.0
ICD-10	44 (31)	6 (37.5)	0.60 °
Specialty visit			
Pulmonary only	71 (50)	10 (63)	
Other specialists			
(including multiple)	54 (38)	3 (18.5)	0.28 ^b
Primary care only	17 (12)	3 (18.5)	

Ophthalmology visit	120 (84.5)	13 (81.2)	0.93 °
Organ involvement			I
Lung	86 (60.5)	12 (75)	
Multiorgan			
(pulmonary without	39 (27.5)	2 (12.5)	
cardiac involvement)			
Multiorgan (cardiac			
without pulmonary	2 (1.4)	0 (0)	
involvement)			
Multiorgan (not			0.38 ^b
cardiac neither	11 (7 0)		
pulmonary	11 (7.8)	2 (0)	
involvement)			
Multiorgan (both			
cardiac and			
pulmonary	4 (2.8) 0 (0)		
involvement)			
EKG	118 (83.1)	13 (81.3)	0.97 °
PFT pattern ^d		<u> </u>	
Obstructive	27 (19)	1 (6.2)	
Restrictive	30 (21.1)	6 (37.5)	0.03 ^b
Mixed	20 (14)	5 (31.3)	0.03 °
Normal	39 (27.5)	1 (6.2)	
CXR	129 (90.8)	14 (87.5)	0.93 °
25(OH)D	72 (50.7)	10 (62.5)	
1,25(OH)D	31 (21.8)	5 (31.3)	0.80 °
Both (1,25 and 25 (OH)D)	31(21.8)	1(6.2)	

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

Stage 0	24 (16.9)	5 (31.2)	
Stage I	23 (16.2)	3 (18.8)	_
Stage II	45 (31.7)	2 (12.5)	0.06
Stage III	17 (12)	4 (25)	_
Stage IV	22 (15.5)	0 (0)	
nical Phenotype Group ^f			
Group 1: Multiorgan	50 (35.2)	2 (12.5)	
Group 2: Nonacute,		2 (12 5)	
Stage I, untreated	6 (4.2)	2 (12.5)	
Group 3: Stage II-III,	42 (29.6)	3 (18.8)	
treated	42 (27.0)	5 (10.0)	
Group 4: Stage II-III,	14 (0 0)	2 (12 5)	
untreated	14 (9.9)	2 (12.5)	
Group 5: Stage IV,	17 (12)	0.(0)	
treated	17 (12)	0 (0)	0.06
Group 6: Stage IV,	4 (2 8)	2 (12 5)	0.00
untreated	4 (2.8)	2 (12.5)	
Group 7: Acute			
sarcoidosis,	0 (0)	0 (0)	
untreated			
Group 8: Remitting,	30 (21)	5 (31)	
untreated	50 (21)	5 (51)	
Group 9: Cardiac	6(42)	0.00	_
sarcoidosis, treated	6 (4.2)	0 (0.0)	

418

419 ^a Based on the clinical diagnostic criteria recommended by the American Thoracic Society (clinical, radiographic,

420 and pathological findings) in the absence of other alternative diagnoses that could explain the presence of non-

421 necrotizing granulomas on histopathology.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 422 ^b Fisher's exact test.
- 423 ° X² test.
- 424 ^d Evaluated based on pulmonary function tests reports available in CPRS.
- 425 ^e Scored based on reviewers' interpretation of imaging reports using Scadding staging. Stage 0: normal chest
- 426 radiograph, Stage I: hilar or mediastinal nodal enlargement only; Stage II: nodal enlargement and parenchymal
- 427 disease; Stage III: parenchymal disease only; Stage IV: end-stage lung disease (pulmonary fibrosis).
- 428 ^g Clinical Phenotype Groups [11]:
- 429 Group 1: Multiorgan involvement: Patients with more than 2 organs involved.
- 430 Group 2: Nonacute, Stage I, untreated: Patients with nonacute sarcoidosis, Stage I, never treated for sarcoidosis.
- 431 Group 3: Stage II-III, treated: Patients with nonacute sarcoidosis, Stage II or III, formerly treated for sarcoidosis
- 432 or treated within 3 months of data review.
- 433 Group 4: Stage II-III, untreated: Patients with nonacute sarcoidosis, Stage II or III, never treated for sarcoidosis.
- 434 Group 5: Stage IV, treated: Patients with nonacute sarcoidosis, Stage IV, formerly treated for sarcoidosis or treated 435 within 3 months of data review.
- 436 Group 6: Stage IV, untreated: Patients with nonacute sarcoidosis, Stage IV, never treated for sarcoidosis.
- 437 Group 7: Acute sarcoidosis, untreated: Patients with acute sarcoidosis (Löfgren syndrome).
- 438 Group 8: Remitting, untreated: Patients who have had no evidence of active clinical disease for more than one 439 year.
- 440 Group 9: Cardiac sarcoidosis, treated: Patients with cardiac manifestations of sarcoidosis, formerly treated for
- 441 sarcoidosis or treated within 3 months of data review.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

442 Table 2. Contingency 2x2 table of using ICD and index of suspicion for sarcoidosis cases

443 identification.

	Index of Suspicion ^a	Sarcoidosis confirmed with a biopsy		
		Yes ^b	No ^c	Total
Patients with	High index of	142 ^d	16 ^e	158
positive ICD 9	suspicion			
or ICD-10 for	Low index of	0 ^f	42 ^g	42
sarcoidosis	suspicion			
	Total	142	58	200

444

445 ^a Index of suspicion for sarcoidosis based on both clinical and radiographic evidence but not biopsy.

446 ^b Available biopsies with primary or secondary histopathological reports.

447 ^c No biopsies were ordered or available in the electronic medical record.

448 ^d Probable sarcoidosis group with histopathological evidence of non-necrotizing granuloma (NNG) = true 449 positives

450 ^e Probable sarcoidosis group without histopathological evidence of NNG= false positives

451 ^f No sarcoidosis group due to lack of sufficient clinical and radiological features consistent with sarcoidosis even

452 in the presence of the histopathological evidence of NNG = false negatives

453 ^g No sarcoidosis group due to lack of sufficient clinical and radiological features consistent with sarcoidosis, in

454 addition to the absence of the histopathological evidence of NNG= true negatives

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

455 **Table 3.** Healthcare providers' compliance with the ATS clinical practice guideline.

Healthcare providers' compliance with	Probable sarcoidosis	Probable sarcoidosis
ATS practice guidelines ^a	with confirmed biopsy	without confirmed biopsy
N (%)	N=142	N= 16
Fully compliant	26 (18.3)	1 (6.25)
Substantially compliant	76 (53.5)	8 (50)
Partially compliant	31 (21.9)	6 (37.5)
Non-compliant	9 (6.3)	1 (6.25)

456

⁴⁵⁷ ^a Developed with modifications based on recently published ATS practice guideline. The scoring system has

458 been developed based on the availability of the following within one year of the diagnosis: ophthalmology visit

459 = 3 points, 12-leads EKG = 3 points, CXR = 3 points, vitamin D (25-OH + 1,25-OH = 3 points; 25(OH)D or

460 1,25(OH)D = 2 points, otherwise zero points). Each variable weight a score of 3, with a total score of 12. Each

461 patient was given a final score, and the purpose was to classify the degree of the providers' compliance into four 462 categories based on the score:

463 o *Fully compliant*: if the score = 12

464 o *Substantially compliant*: if the score = 9-11

465 o *Partially compliant*: if the score = 5-8

466 o *Non-compliant*: if the score <5.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

Table 4. Contingency 2x2 table of the healthcare providers' compliance score by primary 467

468 versus specialty care ^a.

Healthcare providers' compliance with	Healthcare providers			
ATS practice guideline scored by our	Specialists	Primary care	Total	
classification	Specialists	physicians	Total	
"Fully" or "Substantially"	102	9	111	
compliant	102	,	111	
"Partially" or "Non" compliant	36	11	47	
Total	138	20	158	

469

470 ^a X^2 statistic= 6.9877, P-value= 0.008.

471	Ethics approval and consent to participate: The University of California San Francisco
472	Institutional Review Board and the Veterans Health Administration Research and
473	Development Committee approved this study. [IRB Protocol #15-16660].
474	
475	Availability of data and material: Due to the sensitive nature of health data analyzed in the
476	current study, data will remain confidential and are not publicly available.
477 478	Competing interests: The authors have no conflicts of interest to disclose relevant to the
479	present work.
480	Funding: This work was supported by funds from the Department of Veterans Affairs
481	Fellowship Award to MIS; the Flight Attendants Medical Research Institute (FAMRI)
482	(CIA190001 to MA); Department of Veterans Affairs Clinical Sciences Research and
483	Development (CSRD) (CXV-00125 to MA); the Tobacco-related Disease Research Program
484	of the University of California (T29IR0715 to MA).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

485 **Bibliography**

- 486 [1] Judson MA. Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep
 487 2014;6:89. doi:10.12703/P6-89.
- 488 [2] Keller AZ. Anatomic sites, age attributes, and rates of sarcoidosis in U. S. veterans.
 489 Am Rev Respir Dis 1973;107:615–20. doi:10.1164/arrd.1973.107.4.615.
- 490 [3] Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al.
 491 Diagnosis and detection of sarcoidosis. an official american thoracic society clinical
 492 practice guideline. Am J Respir Crit Care Med 2020;201:e26–51.
- 493 doi:10.1164/rccm.202002-0251ST.
- 494 [4] Judson MA. The diagnosis of sarcoidosis. Curr Opin Pulm Med 2019;25:484–96.
 495 doi:10.1097/MCP.0000000000596.
- 496 [5] Szeto HC, Coleman RK, Gholami P, Hoffman BB, Goldstein MK. Accuracy of
 497 computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. Am J
 498 Manag Care 2002;8:37–43.
- 499 [6] Pendergrass SA, Crawford DC. Using electronic health records to generate phenotypes
 500 for research. Curr Protoc Hum Genet 2019;100:e80. doi:10.1002/cphg.80.
- 501 [7] Horsky J, Drucker EA, Ramelson HZ. Accuracy and Completeness of Clinical Coding
 502 Using ICD-10 for Ambulatory Visits. AMIA Annu Symp Proc 2017;2017:912–20.
- 503 [8] Ungprasert P, Matteson EL, Crowson CS. Accuracy of Diagnostic Coding for
 504 Sarcoidosis in Electronic Databases: A Population-Based Study. Lung 2017;195:713–5.
 505 doi:10.1007/s00408-017-0054-x.
- Velarde KE, Romesser JM, Johnson MR, Clegg DO, Efimova O, Oostema SJ, et al. An
 initiative using informatics to facilitate clinical research planning and recruitment in the
 VA health care system. Contemp Clin Trials Commun 2018;11:107–12.
 doi:10.1016/j.conctc.2018.07.001.
- 510 [10] Sampling Essentials: Practical Guidelines for Making Sampling Choices SAGE
 511 Research Methods n.d. https://dx.doi.org/10.4135/9781452272047 (accessed December
 512 23, 2020).
- [11] Moller DR, Koth LL, Maier LA, Morris A, Drake W, Rossman M, et al. Rationale and
 Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis
 (GRADS) Study. Sarcoidosis Protocol. Annals of the American Thoracic Society
 2015;12:1561–71. doi:10.1513/AnnalsATS.201503-172OT.
- 517 [12] Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al.
 518 Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir
 519 Crit Care Med 2001;164:1885–9. doi:10.1164/ajrccm.164.10.2104046.
- 520 [13] National Center for Veteran Analysis and Statistics. Department of Veterans Affairs
 521 Statistics at A Glance (Updated 12/31/2019). February 2020. n.d.
 522 https://www.va.gov/vetdata/docs/Quickfacts/Stats_at_a_glance_4_6_20.PDF (accessed
 523 January 1, 2021).
- 524 [14] Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial
 525 difference in sarcoidosis mortality in the United States. Chest 2015;147:438–49.
 526 doi:10.1378/chest.14-1120.
- 527 [15] Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis
 528 in black women in the United States: data from the Black Women's Health Study.
 529 Chest 2011;139:144–50. doi:10.1378/chest.10-0413.
- [16] Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J
 Epidemiol 1997;145:234–41. doi:10.1093/oxfordjournals.aje.a009096.
- 533 [17] Brito-Zerón P, Kostov B, Superville D, Baughman RP, Ramos-Casals M, Autoimmune
 534 Big Data Study Group. Geoepidemiological big data approach to sarcoidosis:

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- geographical and ethnic determinants. Clin Exp Rheumatol 2019;37:1052–64.
 [18] Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence,
- 537 prevalence and risk factors. Curr Opin Pulm Med 2020;26:527–34.
 538 doi:10.1097/MCP.00000000000715.
- 539 [19] Minority Veteran Statistics n.d.
- 540https://www.va.gov/HEALTHEQUITY/Race_Ethnicity.asp?utm_content&utm_mediu541m=email&utm_name&utm_source=govdelivery&utm_term (accessed January 1,5422021).
- 543 [20] Organization WH. The ICD-10 Classification of Mental and Behavioural Disorders:
 544 Diagnostic Criteria for Research. New Edition. Geneva: World Health Organization;
 545 1993.
- 546 [21] Scadding JG. Prognosis of intrathoracic sarcoidosis in england. BMJ 1961;2:1165–72.
 547 doi:10.1136/bmj.2.5261.1165.
- 548 [22] Su R, Li MM, Bhakta NR, Solberg OD, Darnell EPB, Ramstein J, et al. Longitudinal
 549 analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur
 550 Respir J 2014;44:985–93. doi:10.1183/09031936.00039714.
- [23] Zhou T, Zhang W, Sweiss NJ, Chen ES, Moller DR, Knox KS, et al. Peripheral blood
 gene expression as a novel genomic biomarker in complicated sarcoidosis. PLoS One
 2012;7:e44818. doi:10.1371/journal.pone.0044818.
- Maier LA, Crouser ED, Martin WJ, Eu J. Executive summary of the NHLBI workshop
 report: leveraging current scientific advancements to understand sarcoidosis variability
 and improve outcomes. Annals of the American Thoracic Society 2017;14:S415–20.
 doi:10.1513/AnnalsATS.201707-563OT.
- 558 [25] Sharma H, Mao C, Zhang Y, Vatani H, Yao L, Zhong Y, et al. Developing a portable
 559 natural language processing based phenotyping system. BMC Med Inform Decis Mak
 560 2019;19:78. doi:10.1186/s12911-019-0786-z.
- 561 [26] Richesson R. Electronic Health Records-Based Phenotyping n.d.
- 562 [27] Paul DW, Neely NB, Clement M, Riley I, Al-Hegelan M, Phelan M, et al.
- 563 Development and validation of an electronic medical record (EMR)-based computed 564 phenotype of HIV-1 infection. J Am Med Inform Assoc 2018;25:150–7. 565 doi:10.1093/jamia/ocx061.
- 566

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

567 **FIGURE LEGENDS**

- 568
- 569 Figure 1. STROBE flow chart. Selection criteria for probable sarcoidosis cases.
- 570 Abbreviations: ATS, American Thoracic Society; ICD, International Classification of
- 571 Diseases; PA, Palo Alto; SF, San Francisco; VA, Veterans Affairs
- 572


573 Figure 2. Organ involvement assessment for probable sarcoidosis with and without

- 574 confirmed biopsy. <u>Abbreviations</u>: AV, atrioventricular; CNS, central nervous system; CT,
- 575 computed tomography; CXR, chest radiograph; DLCO, diffusing capacity for carbon
- 576 monoxide; EKG, electrocardiogram; ENT, ears, nose and throat; MRI, magnetic resonance
- 577 imaging; PET, positron emission tomography; PFT, pulmonary function test.
- 578
- 579 Figure 3. Distribution of characteristics among patients with probable sarcoidosis with
- 580 and without confirmed biopsy. <u>Abbreviations:</u> PFT, pulmonary function test; ICD,
- 581 International Classification of Diseases.
- 582

Figure 4. Comparison of specialty visits across cases with probable sarcoidosis (with and without confirmed biopsy) and with healthcare providers classified as "Fully" or "Substantially" compliant vs. "Partially" or "Non-" compliant using our compliance scoring system.

- 588 Acknowledgment: The Author(s) confirmed no figures or tables included from another
- 589 publication.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)





591


593 Figure 1. STROBE flow chart. Selection criteria for probable sarcoidosis cases.

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)

	Organ involvement
Lung	 Positive lung biopsy, positive mediastinal/hilar lymph node biopsy Chest X-ray/CT scan/PET scan demonstrating bilateral hilar lymphadenopathy, CT scan with perilymphatic nodules tracking the bronchovascular bundle, chest X-ray/CT scan/PET scan with diffuse infiltrates, chest X-ray with fibrosis PFT with restriction and low DLCO or isolated reduced DLCO
Skin	 Positive skin biopsy Lupus pernio and erythema nodosum ^a
Eye	Positive conjunctival or scleral biopsyOptic neuritis, scleritis, uveitis, or retinitis
Cardiac	 Positive heart/pericardium biopsy 12-lead EKG showing Mobitz II or III-degree AV node block AV node block or cardiomyopathy responsive to treatment Cardiac MRI or PET-CT consistent with sarcoidosis
Liver	 Positive liver biopsy with a positive biopsy from another organ Evidence of hepatomegaly Abnormal liver enzymes
Multiorgan involvement	• More than two organs involved based on other criteria in this table
Neurosarcoidosis	 Positive brain/dura/peripheral nerve biopsy Clinical syndrome or symptoms consistent with CNS sarcoidosis along with a positive MRI
ENT	Positive biopsy from ear, nose, or throatDirect laryngoscopy consistent with granulomatous disease


Figure 2. Organ involvement assessment for probable sarcoidosis with and without confirmed biopsy ^a.

^a No biopsy is needed for acute skin sarcoidosis.




perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)




perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)



perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)




609 610



perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Mohamed I Seedahmed (https://orcid.org/0000-0002-7446-7346)





616

617 Figure 3. Distribution of characteristics among patients with probable sarcoidosis with and

618 without confirmed biopsy.

619 <u>Abbreviations:</u> PFT, pulmonary function test; ICD, International Classification of Diseases








Figure 4. Comparison of specialty visits across cases with probable sarcoidosis (with and
without confirmed biopsy) and with healthcare providers classified as "Fully" or
"Substantially" compliant vs. "Partially" or "Non-" compliant using our compliance scoring
system.